Shenzhen Salubris Pharmaceuticals Co., Ltd. (SZSE:002294) intends to sign an equity transfer agreement to acquire remaining 15.7% stake in Salubris (Suzhou) Pharmaceutical Co., Ltd. from a group of shareholders for approximately CNY 240 million on April 11, 2020. At present, Salubris owns a 84.27% stake in Salubris (Suzhou) Pharmaceutical Co., Ltd. After acquisition, it will own a 100% stake. For the year ended December 31, 2019, Salubris (Suzhou) Pharmaceutical Co., Ltd. has total assets of CNY 391 million, net assets of CNY 366.9 million, owners equity of CNY 366.9 million, operating revenue of CNY 2.6 million, operating loss and net loss of CNY 153.9 million. Payment will be done in 4 installments. The transaction was approved by the 3rd meeting o the 5th Directorate of Salubris. Shenzhen Salubris Pharmaceuticals Co., Ltd. (SZSE:002294) completed the acquisition of remaining 15.7% stake in Salubris (Suzhou) Pharmaceutical Co., Ltd. from a group of shareholders recently.